Metastatic Group 3 Medulloblastoma in a Patient With Tuberous Sclerosis Complex: Case Description and Molecular Characterization of the Tumor

Romina Moavero, Valentina Folgiero, Andrea Carai, Evelina Miele, Elisabetta Ferretti, Agnese Po, Francesca Diomedi Camassei, Francesca Romana Lepri, Federico Vigevano, Paolo Curatolo, Massimiliano Valeriani, Giovanna S. Colafati, Franco Locatelli, Assunta Tornesello, Angela Mastronuzzi

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Medulloblastoma is the most common pediatric brain tumor. We describe a child with tuberous sclerosis complex that developed a Group 3, myc overexpressed, metastatic medulloblastoma (MB). Considering the high risk of treatment-induced malignancies, a tailored therapy, omitting radiation, was given. Based on the evidence of mammalian target of rapamycin mTORC, mTOR Complex; RAS, Rat sarcoma; RAF, rapidly accelerated fibrosarcoma (mTOR) pathway activation in the tumor, targeted therapy was applied resulting in complete remission of disease. Although the PI3K/AKT/mTOR signaling pathway plays a role in MB, we did not find TSC1/TSC2 (TSC, tuberous sclerosis complex) mutation in our patient. We speculate that a different pathway resulting in mTOR activation is the basis of both TSC and MB in this child; H&E, haematoxilin and eosin; Gd, gadolinium.

Original languageEnglish
Pages (from-to)719-722
Number of pages4
JournalPediatric Blood and Cancer
Volume63
Issue number4
DOIs
Publication statusPublished - Apr 1 2016

Fingerprint

Medulloblastoma
Tuberous Sclerosis
Neoplasms
Fibrosarcoma
Gadolinium
Sirolimus
Eosine Yellowish-(YS)
Phosphatidylinositol 3-Kinases
Brain Neoplasms
Sarcoma
Radiotherapy
Pediatrics
Mutation
Therapeutics

Keywords

  • Medulloblastoma
  • MTOR
  • TSC1/2

ASJC Scopus subject areas

  • Oncology
  • Pediatrics, Perinatology, and Child Health
  • Hematology

Cite this

Metastatic Group 3 Medulloblastoma in a Patient With Tuberous Sclerosis Complex : Case Description and Molecular Characterization of the Tumor. / Moavero, Romina; Folgiero, Valentina; Carai, Andrea; Miele, Evelina; Ferretti, Elisabetta; Po, Agnese; Diomedi Camassei, Francesca; Lepri, Francesca Romana; Vigevano, Federico; Curatolo, Paolo; Valeriani, Massimiliano; Colafati, Giovanna S.; Locatelli, Franco; Tornesello, Assunta; Mastronuzzi, Angela.

In: Pediatric Blood and Cancer, Vol. 63, No. 4, 01.04.2016, p. 719-722.

Research output: Contribution to journalArticle

@article{5232f59752af4b9882ac1f7d6370754a,
title = "Metastatic Group 3 Medulloblastoma in a Patient With Tuberous Sclerosis Complex: Case Description and Molecular Characterization of the Tumor",
abstract = "Medulloblastoma is the most common pediatric brain tumor. We describe a child with tuberous sclerosis complex that developed a Group 3, myc overexpressed, metastatic medulloblastoma (MB). Considering the high risk of treatment-induced malignancies, a tailored therapy, omitting radiation, was given. Based on the evidence of mammalian target of rapamycin mTORC, mTOR Complex; RAS, Rat sarcoma; RAF, rapidly accelerated fibrosarcoma (mTOR) pathway activation in the tumor, targeted therapy was applied resulting in complete remission of disease. Although the PI3K/AKT/mTOR signaling pathway plays a role in MB, we did not find TSC1/TSC2 (TSC, tuberous sclerosis complex) mutation in our patient. We speculate that a different pathway resulting in mTOR activation is the basis of both TSC and MB in this child; H&E, haematoxilin and eosin; Gd, gadolinium.",
keywords = "Medulloblastoma, MTOR, TSC1/2",
author = "Romina Moavero and Valentina Folgiero and Andrea Carai and Evelina Miele and Elisabetta Ferretti and Agnese Po and {Diomedi Camassei}, Francesca and Lepri, {Francesca Romana} and Federico Vigevano and Paolo Curatolo and Massimiliano Valeriani and Colafati, {Giovanna S.} and Franco Locatelli and Assunta Tornesello and Angela Mastronuzzi",
year = "2016",
month = "4",
day = "1",
doi = "10.1002/pbc.25851",
language = "English",
volume = "63",
pages = "719--722",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "John Wiley and Sons Inc.",
number = "4",

}

TY - JOUR

T1 - Metastatic Group 3 Medulloblastoma in a Patient With Tuberous Sclerosis Complex

T2 - Case Description and Molecular Characterization of the Tumor

AU - Moavero, Romina

AU - Folgiero, Valentina

AU - Carai, Andrea

AU - Miele, Evelina

AU - Ferretti, Elisabetta

AU - Po, Agnese

AU - Diomedi Camassei, Francesca

AU - Lepri, Francesca Romana

AU - Vigevano, Federico

AU - Curatolo, Paolo

AU - Valeriani, Massimiliano

AU - Colafati, Giovanna S.

AU - Locatelli, Franco

AU - Tornesello, Assunta

AU - Mastronuzzi, Angela

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Medulloblastoma is the most common pediatric brain tumor. We describe a child with tuberous sclerosis complex that developed a Group 3, myc overexpressed, metastatic medulloblastoma (MB). Considering the high risk of treatment-induced malignancies, a tailored therapy, omitting radiation, was given. Based on the evidence of mammalian target of rapamycin mTORC, mTOR Complex; RAS, Rat sarcoma; RAF, rapidly accelerated fibrosarcoma (mTOR) pathway activation in the tumor, targeted therapy was applied resulting in complete remission of disease. Although the PI3K/AKT/mTOR signaling pathway plays a role in MB, we did not find TSC1/TSC2 (TSC, tuberous sclerosis complex) mutation in our patient. We speculate that a different pathway resulting in mTOR activation is the basis of both TSC and MB in this child; H&E, haematoxilin and eosin; Gd, gadolinium.

AB - Medulloblastoma is the most common pediatric brain tumor. We describe a child with tuberous sclerosis complex that developed a Group 3, myc overexpressed, metastatic medulloblastoma (MB). Considering the high risk of treatment-induced malignancies, a tailored therapy, omitting radiation, was given. Based on the evidence of mammalian target of rapamycin mTORC, mTOR Complex; RAS, Rat sarcoma; RAF, rapidly accelerated fibrosarcoma (mTOR) pathway activation in the tumor, targeted therapy was applied resulting in complete remission of disease. Although the PI3K/AKT/mTOR signaling pathway plays a role in MB, we did not find TSC1/TSC2 (TSC, tuberous sclerosis complex) mutation in our patient. We speculate that a different pathway resulting in mTOR activation is the basis of both TSC and MB in this child; H&E, haematoxilin and eosin; Gd, gadolinium.

KW - Medulloblastoma

KW - MTOR

KW - TSC1/2

UR - http://www.scopus.com/inward/record.url?scp=84959556506&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959556506&partnerID=8YFLogxK

U2 - 10.1002/pbc.25851

DO - 10.1002/pbc.25851

M3 - Article

C2 - 26626406

AN - SCOPUS:84959556506

VL - 63

SP - 719

EP - 722

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 4

ER -